Abhishek Agnihotri, MD
Gastroenterology · Dover, DENPI 1174906622
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $27,514 with a category attached, or 90.9%. Boston Scientific accounts for 97.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $25,157 and has fallen 99.5% since, to $127 in 2025. Among gastroenterology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $982.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$27K
- Ovesco Endoscopy USA, Inc.$595
- Fujifilm Healthcare Americas Corporation$54
- Micro-tech Endoscopy USA, Inc.$12
What the payments were for
- Grants$25,00091%
- Travel & lodging$1,6666%
- Food & beverage$8483%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $26,853 |
| Ovesco Endoscopy USA, Inc. | 1 | $595 |
| Fujifilm Healthcare Americas Corporation | 1 | $54 |
| Micro-tech Endoscopy USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - BILIARY DEVICES$25,000
- GENERAL - THERAPIES$1,099
- EXALT Model D$116
- SPYGLASS$100
How this compares
$27,514 in reported general payments places this provider in the 95th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $169,115 |
| CreonLipase/Protease/Amylase | 17 | $48,656 |
| LinzessLinaclotide | 30 | $15,082 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 72 | $3,987 |
| Omeprazole | 114 | $2,703 |
| Pantoprazole Sodium | 115 | $1,729 |
| Dexlansoprazole DrDexlansoprazole | 12 | $1,623 |
| Esomeprazole Magnesium | 22 | $1,325 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $238 |
| Dicyclomine Hcl | 17 | $200 |
| Ondansetron OdtOndansetron | 14 | $148 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dover
- Bhavin DaveDover$11K
- Michal BartelDover$6K
- Temitayo GboluajeDover$2K
- Mithil Gowda SureshDover$2K
- Muhammad HanafiDover$619
- Michael BrooksNewark$48K
- Richard CarusoLewes$13K
- Michael BassWilmington$11K
- Christopher RuffiniNeward$11K
- Jorge UribeNewark$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.